Filter posts

BIO's Leadership Transition | "The fight continues..."

On Tuesday, October 8, BIO formally announced that its President and CEO Jim Greenwood would …

The Right Way to Address Prescription Drug Costs

Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City …

Road to 2018 Farm Bill Was Years in the Making

The following piece appeared in Biofuels Digest from BIO’s Executive Vice President for Industrial & …

Think the Drug-Pricing debate addresses Patient Costs? Think again.

Writing for The Hill, BIO President and CEO Jim Greenwood tackled the drug pricing debate …

BIO Chimes In: TC Heartland LLC v. Kraft Food Brands Group LLC (Supreme Court)

This is part two of a three part series on BIO’s recently submitted amicus briefs in cases …

Four Former FDA Commissioners Warn About Drug Importation Dangers

Last week, four former FDA Commissioners – Robert M. Califf, Margaret B. Hamburg, Mark B. …

ICYMI: The Hill Op-Ed on Ending 340B Abuse

Writing in The Hill today, Ellen Weaver of the Palmetto Promise Institute and Lindsay Boyd …

BIO on CNBC: IPR System Weakens Medical Innovation

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on …

Here are the Facts about the IPR Kill Rate

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the …

Reflecting on July 2015: “The Ag Biotech Debate Was Front and Center”

Agri-Pulse recently published an op-ed titled “The Biotechnology Riddle” by Marshall Matz which outlined how …